federal regulators canceled a meeting around the company's experimental drug to treat a debilitating liver condition. The delayed meeting with the Food

federal regulators canceled a meeting around the company's experimental drug to treat a debilitating liver condition. The delayed meeting with the Food and Drug Administration essentially let loose a domino action: The company's future clinical trial plans are set back and it must find ways to reduce its cash burn in the meantime.